The company has significantly bolstered its financial position, reporting $1.3 billion in total equity and a 2.09 current ratio, though it now carries a debt-to-equity ratio of 1.05 to support its clinical-stage operations.
| Total Current Assets | 1.28B | 1.35B | 2.71M | 5.73M | 0 | 104.16K |
| Cash & Short-Term Investments | 272.15M | 389.89M | 554K | 4.23M | 0 | 48.55K |
| Cash Only | 272.15M | 389.89M | 554K | 4.23M | 0 | 48.55K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 499.09M | 462.85M | 489K | 0 | 0 | 0 |
| Days Sales Outstanding | 126.13 | - | - | - | - | - |
| Inventory | 423.12M | 402.35M | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 171.86 | - | - | - | - | - |
| Other Current Assets | 85.52M | 94.3M | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 2.18B | 2.19B | 1.48M | 1.49M | 5K | 108.96K |
| Property, Plant & Equipment | 569.39M | 566.02M | 303K | 0 | 0 | 0 |
| Fixed Asset Turnover | 2.45x | - | - | - | - | - |
| Goodwill | 1.03B | 1.04B | 1.02B | 0 | 0 | 0 |
| Intangible Assets | 392.43M | 399.8M | 419.07M | 0 | 5K | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 169.58M | 177.09M | -1.44B | 1.49M | 0 | 108.96K |
| Total Assets | 3.46B | 3.54B | 4.19M | 7.22M | 5K | 213.13K |
| Asset Turnover | 0.40x | - | - | - | - | - |
| Asset Growth % | 131893.68% | 84412.78% | -41.96% | 144380% | -97.65% | - |
| Total Current Liabilities | 613.63M | 697.5M | 10.74M | 1.8M | 4.18M | 192.51K |
| Accounts Payable | 326.93M | 361.43M | 1.43M | 215K | 0 | 0 |
| Days Payables Outstanding | 143.7 | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 7.23M | 985K | 175K | 177.06K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 3.29M | 15.45K |
| Current Ratio | 2.09x | 1.93x | 0.25x | 3.18x | - | 0.54x |
| Quick Ratio | 1.40x | 1.36x | 0.25x | 3.18x | - | 0.54x |
| Cash Conversion Cycle | 154.29 | - | - | - | - | - |
| Total Non-Current Liabilities | 1.56B | 1.58B | 245K | 5.88M | 5.92M | 0 |
| Long-Term Debt | 1.26B | 1.29B | 0 | 0 | 1.83M | 0 |
| Capital Lease Obligations | 89.93M | 0 | 107K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 210.52M | 98.06M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 100.1M | 197.97M | 138K | 5.88M | -545.75K | 0 |
| Total Liabilities | 2.18B | 2.28B | 10.99M | 7.68M | 10.09M | 192.51K |
| Total Debt | 1.35B | 1.29B | 7.46M | 985K | 2.01M | 177.06K |
| Net Debt | 1.08B | 895.78M | 6.9M | -3.24M | 2.01M | 128.5K |
| Debt / Equity | 1.05x | 1.02x | - | - | - | 8.59x |
| Debt / EBITDA | 16.59x | - | - | 0.32x | - | - |
| Net Debt / EBITDA | 13.24x | - | - | -1.06x | - | - |
| Interest Coverage | 3.08x | -121.96x | -10.82x | 14.47x | - | - |
| Total Equity | 1.28B | 1.26B | -6.79M | -457K | -10.09M | 20.62K |
| Equity Growth % | 66673.62% | 18713.63% | -1386.43% | 95.47% | -49030.6% | - |
| Book Value per Share | 32567.61 | 37970.69 | -23502.59 | -2019.33 | -41567.68 | 357.86 |
| Total Shareholders' Equity | 1.28B | 1.26B | -6.79M | -457K | -10.09M | 20.62K |
| Common Stock | 503K | 503K | 14K | 7K | 6K | 331 |
| Retained Earnings | 1.45B | 1.41B | -29.1M | -11.3M | -10.77M | -4.38K |
| Treasury Stock | -939.15M | -911.9M | 0 | 0 | 0 | 0 |
| Accumulated OCI | -95.72M | -97.2M | 414K | 411K | 675K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical asset valuation volatility
According to recent financial statements, CDT's total assets surged from $7.3 million in 2025Q1 to $3.5 billion by 2026Q1, signaling a fundamental shift in the company's scale as it transitions from a dormant development entity into an active clinical-stage biotechnology platform.
This dramatic expansion in the asset base appears to be driven by the aggressive acquisition of clinical programs and intellectual property. Investors should monitor whether this rapid growth in assets translates into sustainable long-term value or if it merely reflects an over-capitalized balance sheet awaiting clinical validation.
As reported in the 2026Q1 filings, CDT maintains a debt-to-equity ratio of 1.05, reflecting a deliberate shift toward utilizing debt to finance its clinical facilitation model after operating with negligible leverage throughout the majority of the 2024 fiscal year.
The current debt load of $1.4 billion suggests management is comfortable leveraging the balance sheet to accelerate asset development. While this leverage appears manageable given the current equity base, the reliance on debt to fund clinical trials warrants further investigation into the company's interest coverage capacity.
Based on the 2026Q1 balance sheet, goodwill and intangible assets account for approximately $1.0 billion of the company's $3.5 billion total asset base, highlighting a heavy reliance on the valuation of acquired clinical programs rather than tangible infrastructure.
The concentration of value in intangible assets suggests that the company's financial health is highly sensitive to the success of its clinical pipeline. Any failure in these programs may necessitate significant impairment charges, which could rapidly erode the reported equity position.
Based on reported figures for 2026Q1, CDT maintains a current ratio of 2.09, providing a substantial liquidity buffer that contrasts sharply with the liquidity constraints observed during the company's early development phases in 2024.
The current cash position of $272.2 million appears sufficient to support near-term clinical facilitation activities. However, the rapid consumption of cash for working capital needs suggests that maintaining this liquidity will require disciplined capital allocation as the company scales its operations.
As indicated by the 2026Q1 financial data, CDT has successfully reversed its historical negative equity position, reporting $1.3 billion in total equity, a significant improvement from the deficit of $9.1 million recorded in 2024Q3.
This turnaround in equity quality suggests that the company has successfully recapitalized its operations to support its current growth trajectory. Investors should monitor the impact of potential future share-based compensation and dilution on this newly established equity base.
Quick answers to the most common questions about buying CDT stock.
As of 2025, CDT Equity Inc. (CDT) had total assets of $3.54B including $1.35B in current assets.
CDT Equity Inc. (CDT) carries total debt of $1.29B, offset by $389.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
CDT Equity Inc. (CDT) has total shareholders' equity (book value) of $1.26B ($37970.69 book value per share). Book value represents the net worth of the company belonging to common stock holders.
CDT Equity Inc. (CDT) reported a current ratio of 1.93x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.